Consolidated Statement of Income (s millions) For Fiscal Year Ended April 26, 2019 $30,557 9.155 2330 10 418 1,764 198 166 258 Net sales Costs and expenses Cost of products sold Research and development expense. Selling, general, and administrative expense Amortization of intangible assets Restructuring charges, net Certain litigation charges Other operating expense, net. Operating profit (loss). Other nonoperating income, net. Interest expense. Income (loss) before income taxes Income tax provision. Net income (loss) Net (income) loss attributable to noncontrolling interests. Net income (loss) attributable to Medtronic 6.268 (373) 1,444 5,197 547 4,650 (19) $ 4,631 Use the following assumptions to prepare a forecast of the company's income statement for 720 11-34 Net sales increase Cost of products sold Research and development expense. Selling, general, and administrative expense. Amortization of intangible assets Restructuring charges, net. Certain litigation charge Other operating expense, net. Interest expense Income tax provision. Income attributable to noncontrolling interests. 8% 30.8% of net sales 7.6% of net sales 34.1% of net sales 5.8% of net sales 75% of 2019 restructuring expense $150 million No change in S amount No change in S amount 15% of pretax income No change LO3